Panoptes Pharma is a Vienna-based clinical-stage biotech company specializing in the development of small-molecule therapies for severe eye diseases with high unmet medical needs. Its lead candidate, PP-001, is a next-generation, non-steroidal DHODH inhibitor formulated as both an intravitreal injection (PaniJect) and an eye drop (PaniDrop) for conditions like uveitis, viral conjunctivitis, and dry eye disease. In December 2020, Panoptes was acquired by U.S.-based EyeGate Pharmaceuticals (now Kiora Pharmaceuticals), becoming a wholly owned subsidiary and expanding EyeGate’s pipeline into immunomodulatory treatments for ocular inflammation.
Panoptes
27
May
May
